A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib

A Nexus Consisting of Beta-Catenin and Stat3 Attenuates BRAF Inhibitor Efficacy and Mediates Acquired Resistance to Vemurafenib

Acquired resistance to second generation BRAF inhibitors (BRAFis), like vemurafenib is limiting the benefits of long term targeted therapy for patients with malignant melanomas that harbor BRAF V600 mutations. Since many resistance mechanisms have been described, most of them causing a hyperactivati...

Full description

Bibliographic Details
Main Authors: Tobias Sinnberg, Elena Makino, Marcel A. Krueger, Ana Velic, Boris Macek, Ulrich Rothbauer, Nicola Groll, Oliver Pötz, Stefan Czemmel, Heike Niessner, Friedegund Meier, Kristian Ikenberg, Claus Garbe, Birgit Schittek
Format: Article
Language:English
Published: Elsevier 2016-06-01
Series:EBioMedicine
Subjects:
β-catenin
Melanoma
BRAF
Stat3
Resistance
Vemurafenib
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396416301803

Similar Items

Similar Items